Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Gluten
- Celiac disease (CD)
- Gluten structure
- CD - damaged small intestine lining
- The four degrees of intestinal atrophy in CD
- Genetic basis of CD
- Prevalence of celiac disease
- Reasons for the increased incidence of CD
- Clinical presentations
- Multiple clinical presentations of celiac disease
- Historical photo of celiac child
- The celiac iceberg
- Pathogenesis
- Adverse effects of gluten
- CD pathogenesis
- Food additive breach intestinal permeability
- The HLA-DQ 2/8 grove
- Proinflammatory trigger
- Anti endomysial antibody: marker of CD
- Other serological markers of CD
- Decision flowchart: diagnostic evaluation of CD
- Summary – antibodies in CD
- Sera immunoreactivity of neo-epitopes
- Antibodies’ activity and intestinal damage
- Sensitivity and specificity of CD biomarkers
- High risk groups who should be screened
- The importance of early diagnosis
- Cumulative risk of other autoimmune disease
- The difficulties to follow gluten-free diet
- New therapeutic strategies for CD
- Gluten dependent conditions
- Gluten dependent disease compared to IBS
- The debate continues…
- Cross linking capacities of the mTg
- Pathophysiological summary - tTg
- Pathophysiological summary - mTg
- CD take home messages
- Acknowledgements
Topics Covered
- Celiac disease as a multi-faced, gluten dependent, autoimmune disease
- Substantial change in epidemiology and clinical presentations in the last decades
- The growing list of environmental factors
- Microbial transglutaminase (mTg)
- Diagnostic biomarkers (EMA, tTg, DGP, neo-tTg, neo-mTg)
- Expansion of gluten dependent conditions
- The problem of gluten free diet compliance
- Impacting the environmental factors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lerner, A. (2018, May 1). An update on the multiple faces of celiac disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 1, 2024, from https://doi.org/10.69645/KGTI1661.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Aaron Lerner has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
An update on the multiple faces of celiac disease
A selection of talks on Gastroenterology & Nephrology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Professor Aaron Lerner.
I am a pediatrician,
specializes in Pediatric Gastroenterology and Nutrition,
and the Adult Gastroenterology.
Originally, I am from Israel,
from the Technion - Israel Institute of Technology.
But now, I am doing my research in the Aesku.Kipp Institute in Germany.
We are going to talk about some updates on the multiple faces of Celiac disease.
0:27
In fact, we are talking about a lot of products that contains
gluten and gluten is the main environmental inducer of Celiac disease.
But before starting, let's have a definition.
What is Celiac disease?
0:44
Celiac disease is an autoimmune disorder elicited on
genetically predisposed individuals that are consuming gluten-containing grains.
The gluten is the offending agent but
there are some other prolamins that the patients are not allowed to ingest.
I'm talking about wheat,
barley, rye, and oats.
Epidemiologically speaking, the incidence is one to two percent in the population.
However, there are some Nordic countries like Sweden, Norway,
Ireland, most of the Germany, Finland,
etc, where the incidence is above two percent.
In the last couple of years,
there were some observations that in the Sahara desert,
some tribes, they have
an increased incidence of Celiac disease amounting to six to seven percent.
This is most probably because of genetic inbreeding.
Their disease has some geographical ingredient.
It is much more in the Northern,
in the Western countries.
We are talking about life-long and gluten-dependent autoimmune condition.
Being auto-immune, there is always some genetic aspect to it.
But always, there are environmental factors and more and more,
we are discovering much more environmental factors.
Up 'til now, gluten is the causative.
However, many others associated environmental factors were suggested like infection,
be it viral or bacterial;
the age of the infant; the infant nutrition;
the amount and the type of gluten ingested during the first year of life;
early antibiotics in the first year of life;
microbiota or dysbiota ratio is most probably contributing to a lot of the disease;
and lately, the couple of publication about
industrial processed food additives that they may affect Celiac disease.
Of course nowadays, some modern
lifestyle can affect the disease like the amount of stress, etc.
Clinically speaking, there is epidemiological shift in the disease phenotype.
The disease is much more prevalent in the last three or four decades in advanced age,
and the clinical presentation is much more subtle.
We see more and more latent hypo-symptomatic or asymptomatic presentation.
We know also the evolutionary aspect of wheat might be important because during evolution,
I'm talking about the last 10,000 years,
the gluten content toxicity and immunogenicity is increasing in the wheat.